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Vitamin B12 is an essential micronutrient required for optimal hemopoetic, neuro-cognitive and cardiovascular
function. Biochemical and clinical vitamin B12 deficiency has been demonstrated to be highly prevalent among
patients with type 1 and type 2 diabetes mellitus. It presents with diverse clinical manifestations ranging from
impaired memory, dementia, delirium, peripheral neuropathy, sub acute combined degeneration of the spinal cord,
megaloblastic anemia and pancytopenia. This review article offers a current perspective on the physiological roles
of vitamin B12, proposed pathophysiological mechanisms of vitamin B12 deficiency, screening for vitamin B12
deficiency and vitamin B12 supplementation among patients with diabetes mellitus.
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Vitamin B12 or cobalamin is a water soluble vitamin
that plays a very fundamental role in DNA synthesis,
optimal haemopoesis and neurological function. The
clinical picture of vitamin B12 deficiency hence, is pre-
dominantly of features of haematological and neuro-
cognitive dysfunction [1].
This review will mainly discuss the physiological roles of
vitamin B12, the varied pathophysiological mechanisms of
vitamin B12 deficiency among patients with type 1 and 2
diabetes mellitus (DM) and perspectives on screening for
vitamin B12 deficiency and supplementation of vitamin
B12 among diabetic patients.
Absorption of vitamin B12
The principal source of vitamin B12 is animal proteins.
The preliminary step in the metabolism of vitamin B12
involves its release from animal sources, a process medi-
ated by the action of pepsin and gastric acid. After the
release, dietary vitamin B12 binds to the R-protein se-
creted by the salivary glands. In the duodenum, in the* Correspondence: davouirek@yahoo.co.uk
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distribution, and reproduction in any mediumpresence of an alkaline medium and pancreatic proteases,
the R- protein is hydrolysed to release vitamin B12 which
later binds with the intrinsic factor (IF) secreted by the
gastric parietal cells.
The vitamin B12 –IF complex is highly resistant to pro-
teolytic degradation. The complex attaches at its specific
receptors on the mucosa of the terminal ileum, a site
where its absorption occurs. This stage of vitamin B12
absorption is calcium mediated.
The intracellular vitamin B12 is released following IF
degradation. This free vitamin B12 attaches to another
protein carrier, transcobalamin –II (TC-II) and is later
released into the circulation. This vitamin B12 – TC-II
complex, also referred to as holo TC-II is then actively
taken up by the liver, bone marrow and other vital body
cells. The liver serves as the principal storage site of up
to 90% of the body’s total vitamin B12 [1,2].
A disruption in any of the described steps above will
result into clinical or biochemical vitamin B12 defi-
ciency. This includes insufficient dietary intake especially
among alcoholics and vegetarians and malabsorption
due to several conditions like chronic atrophic gastritis
mainly in the elderly, pernicious anemia, celiac disease,
chronic pancreatitis and drugs like metformin and pro-
ton pump inhibitors (PPIs).d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Vitamin B12 exerts its physiological effects through medi-
ating two principal enzymatic pathways i.e. the methylation
process of homocysteine to methionine and the conversion
of methylmalonyl coenzyme A (CoA) to succinyl-CoA.
Vitamin B12 as a co-factor facilitates the methylation of
homocysteine to methionine which is later activated into
S-adenosyl-methionine that donates its methyl group to
methyl acceptors such as myelin, neurotransmitters and
membrane phospholipids.
Metabolically significant vitamin B12 deficiency hence
will result in disruption of the methylation process and
accumulation of intracellular and serum homocysteine.
Hyperhomocysteinemia has been shown to have poten-
tially toxic effects on neurones and the vascular endo-
thelium. This reaction is also essential in the conversion
of dietary folate (methyl-tetrahydrofolate) to its active
metabolic form, tetrahydrofolate. In another essential
enzymatic pathway, vitamin B12 as a co-factor mediates
the conversion of methylmalonyl coenzyme A (CoA) to
succinyl-CoA. In the presence of vitamin B12 deficiency,
this conversion pathway is diminished and an increase
in the serum methylmalonic acid (MMA) ensues. This is
followed by defective fatty acid synthesis of the neuronal
membranes [3]. Vitamin B12 is also essential in the syn-
thesis of monoamines or neurotransmitters like sero-
tonin and dopamine [4]. This synthesis is impaired with
vitamin B12 deficiency.
All the above collectively explain the resultant neuro-
cognitive or psychiatric manifestations that accompany
vitamin B12 deficiency. Axonal demyelination, degener-
ation and later death are the hallmark of vitamin B12
deficiency induced neuronal damage that manifests as
severe peripheral or autonomic neuropathy, sub acute
combined degeneration of the spinal cord, delirium and
dementia [3,5]. Compelling evidence demonstrates that
hyperhomocysteinemia is also associated with an in-
creased risk of cardiovascular events due to its cellular
and vasculo-toxic effects [6-8].
Vitamin B12 is an essential micronutrient required in
DNA synthesis, cellular repair and normal haemopoesis
together with other micronutrients like folate and iron.
Vitamin B12 deficiency is classically associated with overt
haematological findings like macrocytic red blood cells (mean
cell volume [MCV]> 100 fl) with/without anaemia, ovalocytes,
hyper segmented white blood cells (i.e. >5% of neutrophils
with ≥5 lobes) and pancytopenia [9]. Due to defective cell re-
pair processes, atrophic glossitis, stomatitis andmalabsorption
due to villi atrophy andmucositis are also common.
Vitamin B12 deficiency among patients with type 2 diabetes
mellitus and the general population: a comparative review
Several cross sectional studies [10-12] and case reports
[13-15] have documented an increased frequency ofvitamin B12 deficiency among type 2 DM (T2DM) pa-
tients. Metformin use has been unequivocally demon-
strated as the prime factor associated with vitamin B12
deficiency among patients with T2DM [16-19]. Studies
assessing type 2 diabetic patients on metformin have
reported the prevalence of vitamin B12 deficiency to range
from 5.8% to 33% [10,19,20]. This wide variation in the
reported prevalence could probably be explained by the
varied study definitions of vitamin B12 deficiency. In the
cross sectional study by Pflipsen et al. on 203 outpatient
type 2 diabetic patients at a large military primary care
clinic in USA, definite vitamin B12 deficiency was defined
as serum vitamin B12 concentrations of <100 pg/ml or
elevated serum methylmalonic acid of >243 nmol/L or
homocysteine concentrations of >11.9 nmol/L if serum
vitamin B12 concentrations were between 100 to 350 pg/mL
[10]. Reinstatler et al. in the National Health and Nutrition
Examination Survey of 1999–2006 in the USA de-
fined definite and borderline biochemical vitamin B12
deficiency as serum vitamin B12 concentrations of
≤148 pmol/l and >148-221 pmol/l respectively [19]. In
one cross sectional study that documented a high preva-
lence of vitamin B12 deficiency of 33% among adult
patients with T2DM by Qureshi et al., vitamin B12 defi-
ciency was defined as serum vitamin B12 concentrations
<150 pg/ml [20]. However, patients enrolled in this study
were those who were on high dose (>2 g/day) and long-
term (4 years) metformin treatment, both clinical factors
known to be associated with vitamin B12 deficiency [17,18].
Due to the diverse definitions of vitamin B12 deficiency
used in most studies and the cultural and religious beliefs
in different regions of the world, comparison of the preva-
lence of vitamin B12 deficiency among T2DM patients
and healthy general populations is difficult. In one popula-
tion based study among 1048 elderly Finnish subjects aged
65–100 years, the total prevalence of definite vitamin B12
deficiency was 12.1% [21]. Previously diagnosed vitamin
B12 deficiency was reported among 2.6% of the partici-
pants. Vitamin B12 replacement therapy was documented
among only 2.6% of the participants. In this study, vitamin
B12 deficiency was defined as total serum vitamin B12
concentrations <150 pmol/l or total serum vitamin B12of
150–250 pmol/l and holotranscobalamin ≤37 pmol/l and
homocysteine ≥15 μmol/l.
In India, a country with a large proportion of vegeta-
rians due to cultural and religious beliefs, very high preva-
lence of vitamin B12 deficiency among the general
population has been reported. In one study by Yajnik et al.
to determine the frequency of vitamin B12 deficiency and
hyperhomocysteinemia among 441 healthy middle aged
Indian men, vitamin B12 deficiency as defined by vitamin
B12 concentrations <150 pmol/L was reported among
67% of the study participants [22]. Vegetarian diet was the
sole significant factor associated with low vitamin B12
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CI 2.1-9.3).
In another cross sectional study among 175 healthy eld-
erly Indian subjects aged >60 years, vitamin B12 deficiency
also defined as vitamin B12 concentrations <150 pmol/L
was reported among 16% of the study participants [23].
Elevated serum MMA concentrations which are a more
sensitive indicator of vitamin B12 deficiency were docu-
mented among 55% of the participants.Metformin induced vitamin B12 deficiency among
patients with T2DM
In the absence of contraindications like renal and hep-
atic dysfunction, recent guidelines advocate for the use
of metformin as the first line glucose lowering agent
concurrently with life style modification approaches
[24,25]. Despite its very superior glycemic lowering ef-
fect, metformin has for long been shown to decrease
vitamin B12 levels. In one early randomised controlled
trial by DeFronzo et al., metformin decreased the serum
vitamin B12 levels by 22% and 29% compared to placebo
and glyburide respectively [26]. This side effect of met-
formin has been demonstrated again in several ensuing
cross sectional studies [10-12], case reports [13-15] and
randomised controlled trials [16,17].
The risk of developing metformin associated vitamin
B12 deficiency is greatly influenced by increasing age,
metformin dose and duration of use [17,18]. In a nested
case control study performed among 155 adult Chinese
DM patients on metformin and 310 controls, every 1 g/
day increase in the metformin dose conferred an odds
ratio of 2.9 (95% confidence interval, 2.15-3.87) for de-
veloping vitamin B12 deficiency. Among patients using
metformin for ≥ 3 years, the adjusted odds ratio was 2.4
(95% confidence interval, 1.46-3.91) compared with
those who had received metformin for ≤ 3 years [18].
Decrease in vitamin B12 absorption and levels
following metformin use typically starts as early as
the 4th month [27]. Clinically overt features of vita-
min B12 deficiency manifest by 5–10 years owing to
the large body stores in the liver mainly that are not
quickly depleted [28].
The proposed mechanisms to explain metformin in-
duced vitamin B12 deficiency among patients with T2DM
include: alterations in small bowel motility which stimu-
lates bacterial overgrowth and consequential vitamin B12
deficiency, competitive inhibition or inactivation of vita-
min B12 absorption, alterations in intrinsic factor (IF)
levels and interaction with the cubulin endocytic receptor
[28]. Metformin has also been shown to inhibit the
calcium dependent absorption of the vitamin B12-IF com-
plex at the terminal ileum. This inhibitory effect is re-
versed with calcium supplementation [29].Vitamin B12 deficiency among patients with type 1
diabetes mellitus
Type 1 DM (T1DM) is an auto immune condition that
results from auto immune destruction of insulin secre-
ting beta cells of the pancreas. It is invariably associated
with other organ and non organ specific auto immune
and endocrine conditions leading to development of
autoimmune polyglandular syndromes [30].
Pernicious anemia resulting from chronic autoimmune
gastritis is highly frequent among patients with T1DM.
Chronic autoimmune gastritis and pernicious anemia oc-
curs in about 2% and up to 1% of the general population
respectively. Among patients with T1DM, the prevalence
is increased by 3 to 5 folds [31].
Vitamin B12 deficiency due to pernicious anemia occurs
frequently among patients with T1DM. In one cross sec-
tional study done in South India among 90 patients with
T1DM, low vitamin B12 levels were noted among 45.5%
of the study subjects as defined by the manufactures’ cut
off point of <180 pg/ml and among 54% using the pub-
lished cut off point of <200 pg/ml [32]. No positive corre-
lation was noted between low vitamin B12 levels and
gender, age, duration of DM and level of glycemic control.
Patients with T1DM actively exhibit auto antibodies to
intrinsic factor (AIF) type 1 and 2 [31] and parietal cell
antibodies (PCA) [33,34] especially those with glutamate
decarboxylase-65 (GAD-65) antibodies and HLA-DQA1
*0501-B1*0301 haplotype [35].
The PCA inhibit secretion of intrinsic factor resulting
into pernicious anemia, a condition which is 10 times
more prevalent among type 1 diabetic patients than non
diabetic patients. Type 1 AIF result into vitamin B12 de-
ficiency by blocking the binding of vitamin B12 to IF.
This prevents its transportation to its absorption site,
the terminal ileum. These auto antibodies are found in
70% of patients with pernicious anemia [31].
Primary autoimmune hypothyroidism and celiac dis-
ease are frequent co morbidities among patients with
T1DM [36-38] and directly affect vitamin B12 metabo-
lism [39,40]. In one cross sectional study among 504
ambulatory T1DM patients in South Africa, the overall
prevalence of co-existing auto immune hypothyroidism
was 20.2%, especially among female patients (30.9% Vs
10.1%-males, p<0.0002). Celiac disease in this study co-
hort was reported in 3 (0.6%) patients [37].
Vitamin B12 deficiency among patients with auto-
immune hypothyroidism could be explained by the
presence of antibodies to the gastric parietal cells and
intrinsic factor, reduced oral intake, dyserythropoesis
due to thyroid hormone deficiency and defective ab-
sorption due to reduced bowel motility, bowel wall
oedema and bacterial overgrowth [40].
Celiac disease which is a highly prevalent autoimmune
mediated gastrointestinal condition occurs in 1-16% of
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lation [36]. Ingestion of wheat gluten and other related
proteins have been documented to be the trigger factors of
this condition in genetically susceptible individuals. Due to
the associated enteropathy, patients often present with fail-
ure to thrive, chronic diarrhea and anemia due to micronu-
trient (mainly folate, vitamin B12) malabsorption [41].
Screening approach for vitamin B12 deficiency among
patients with T2DM
Currently, there are no published guidelines advocating
for routine screening for vitamin B12 deficiency among
patients with T2DM. However among type 2 diabetic pa-
tients, it is clinically plausible to screen for vitamin B12
deficiency prior to initiation of metformin and later an-
nually among elderly patients with history of long term
use of metformin (≥3-4 years), use of high doses of met-
formin (≥2 g/day), clinically worsening diabetic distal
polyneuropathy in the presence or absence of the dis-
cussed haematological abnormalities [42].
The screening approach for vitamin B12 deficiency
among diabetic patients and the general population is
similar. Measurement of the serum vitamin B12 concen-
trations should be the preliminary screening step for
vitamin B12 deficiency among patients with T2DM.
Concentrations <200 pg/ml are usually diagnostic of
vitamin B12 deficiency while concentrations >400 pg/ml
confirm absence of vitamin B12 deficiency [43].
Measurement of serum MMA or homocysteine con-
centrations is a more sensitive and specific approach for
screening especially among type 2 diabetic patients with
borderline serum vitamin B12 concentrations of 200-
400 pg/ml and subtle haematological manifestations.
Serum homocysteine and MMA concentrations of 5-
15 μmol/l and <0.28 μmol/l are considered within the
normal range respectively [42,44].
Screening for vitamin B12 deficiency among patients with
T1DM
Among patients with T1DM, there are no clear guide-
lines regarding screening for vitamin B12 deficiency.
However, due to the high prevalence of pernicious an-
aemia and subsequent vitamin B12 deficiency among
T1DM patients reported in most cross sectional studies,
it would be pragmatic to screen at diagnosis and then
later yearly for 3 years, then five yearly thereafter or in
presence of any clinical indication since vitamin B12 de-
ficiency can develop at anytime [31]. Screening should
involve assessment of serum vitamin B12 levels and
markers of gastric autoimmunity like PCA and AIF es-
pecially among T1DM patients with GAD-65 and thy-
roid peroxidase antibodies. Presence of these auto
antibodies increases the propensity to developing vita-
min B12 deficiency [31,45].Treatment of vitamin B12 deficiency among diabetic
patients
Treatment of vitamin B12 deficiency does not differ re-
gardless of the aetiology. All patients deficient of vitamin
B12 should receive replacement therapy with either oral
or parenteral vitamin B12 [46,47]. Both formulations have
been demonstrated to induce comparable desirable haem-
atological and neurological improvements regardless of
the aetiology of the deficiency [48]. In adult patients with
T2DM, intra muscular or oral vitamin B12 in doses of
1000 μg daily for a week then once every week for 4 weeks
are sufficient to correct vitamin B12 deficiency [46,47].
Among young patients with T1DM and co-existing
vitamin B12 deficiency, replacement therapy with daily
intra muscular or oral vitamin B12 in the dose of 100μg
for a week and then monthly is satisfactory. In severe
cases, parenteral or oral administration of 1000 μg/day
of vitamin B12 for a week, followed by the similar dose
given every week for 1 month and then later monthly is
advised [31].
Concomitant folate deficiency should be treated with
oral folate replacement in doses of 5 mg daily for 1–4
months. Folate administration prior to correcting vitamin
B12 deficiency should be avoided because it results into
progression and / worsening of the associated neurological
manifestations [46].
Therapeutic benefits of vitamin B12 replacement among
T2DM patients with diabetic neuropathy.
Vitamin B12 deficiency and the accompanying hyperho-
mocysteinemia and elevated MMA levels have been docu-
mented to cause a distinct sensory polyneuropathy that
closely mimics diabetic neuropathy. Worsening of diabetic
neuropathy is also noted among patients with co-existing
vitamin B12 deficiency [49].
Vitamin B12 replacement has been shown to cause
symptomatic improvement among patients with severe
diabetic neuropathy. One meta-analysis showed that if
used either alone or in combination with vitamin B com-
plex, there was a significant improvement in the somatic
symptoms like pain and paraesthesias. Three included
studies also noted an improvement in autonomic symp-
toms with use of vitamin B12 alone [50].
Similar superior positive findings of reduction in pain
and paraesthesias were also noted with use of vitamin
B12 as compared to nortriptyline in a randomized,
single-blind clinical trial done in Iran among 100 pa-
tients with diabetic neuropathy. This study was approved
by the Ethics review board of the Isfahan University of
Medical Sciences, Iran [51].
Vitamin B12 supplementation among patients with DM
There are no guidelines to address how often patients
with T1DM and T2DM should be supplemented with
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min B12 is also unknown. A recently published follow-
up study from the United States of America showed that
administration of oral vitamin B12 among type 2 DM
patients on long term use of metformin was ineffective
in correcting biochemical vitamin B12 deficiency19. The
doses of vitamin B12 in the multivitamin formulations
used by the study subjects in this survey were probably
inadequate to correct vitamin B12 deficiency.
This stresses the need of further studies to determine
the optimal vitamin B12 supplementation dose and fre-
quency of supplementation among patients with DM.
To avert vitamin B12 deficiency especially among adult
type 2 diabetic patients on long term use of metformin,
it is plausible to adopt a simple and cost effective sup-
plementation approach in diabetes care. A 1000 μg dose
of vitamin B12 given annually would be sufficient to re-
plenish the body’s vitamin B12 stores among this cat-
egory of patients [52].
Conclusions
Clinical and biochemical vitamin B12 deficiency is highly
prevalent among patients with both types 1 and 2 DM.
Future large and well designed studies on screening for
vitamin B12 deficiency, vitamin B12 supplementation and
optimal supplementation dose among type 1 and type 2
diabetic patients are warranted to help guide formulation
of guidelines in diabetes clinical care. Annual screening
for vitamin B12 deficiency using more sensitive methods
like serum homocysteine and methylmalonic acid concen-
trations (in clinical settings where they are accessible) and
supplementation should be adopted among diabetic pa-
tients with specific risk factors of vitamin B12 deficiency.
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